CR20120011A - Inhibidores de bace - Google Patents

Inhibidores de bace

Info

Publication number
CR20120011A
CR20120011A CR20120011A CR20120011A CR20120011A CR 20120011 A CR20120011 A CR 20120011A CR 20120011 A CR20120011 A CR 20120011A CR 20120011 A CR20120011 A CR 20120011A CR 20120011 A CR20120011 A CR 20120011A
Authority
CR
Costa Rica
Prior art keywords
bace inhibitors
methods
bace
inhibitors
intermediaries
Prior art date
Application number
CR20120011A
Other languages
English (en)
Spanish (es)
Inventor
James Edmund Audia
Dustin James Mergott
Chongsheng Eric Shi
Grant Mathews Vaught
Brian Morgan Watson
Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120011(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20120011A publication Critical patent/CR20120011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CR20120011A 2009-07-09 2012-01-09 Inhibidores de bace CR20120011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22424109P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
CR20120011A true CR20120011A (es) 2012-02-09

Family

ID=42985394

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120011A CR20120011A (es) 2009-07-09 2012-01-09 Inhibidores de bace

Country Status (26)

Country Link
US (2) US8278441B2 (enExample)
EP (1) EP2451793B1 (enExample)
JP (1) JP5666578B2 (enExample)
KR (1) KR101362557B1 (enExample)
CN (1) CN102471296B (enExample)
AR (1) AR077277A1 (enExample)
AU (1) AU2010270691B8 (enExample)
BR (1) BR112012000525A2 (enExample)
CA (1) CA2764429C (enExample)
CL (1) CL2012000033A1 (enExample)
CO (1) CO6480979A2 (enExample)
CR (1) CR20120011A (enExample)
DO (1) DOP2012000004A (enExample)
EA (1) EA019892B1 (enExample)
EC (1) ECSP12011581A (enExample)
HN (1) HN2012000012A (enExample)
IL (1) IL216742A0 (enExample)
MA (1) MA33492B1 (enExample)
MX (1) MX2012000510A (enExample)
NZ (1) NZ596579A (enExample)
PE (1) PE20120632A1 (enExample)
SG (1) SG177594A1 (enExample)
TN (1) TN2011000673A1 (enExample)
TW (1) TWI405765B (enExample)
WO (1) WO2011005738A1 (enExample)
ZA (1) ZA201109385B (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2597087B1 (en) 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
HUE026064T2 (en) * 2008-01-18 2016-05-30 Eisai R&D Man Co Ltd Condensed aminodihydrothiazine derivatives
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
ES2433223T3 (es) * 2008-07-28 2013-12-10 Eisai R&D Management Co., Ltd. Derivados de espiroaminodihidrotiazina
ES2539859T3 (es) * 2008-09-30 2015-07-06 Eisai R&D Management Co., Ltd. Nuevo derivado de aminodihidrotiazina condensado
US8703785B2 (en) * 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2511269A4 (en) * 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
JP5711813B2 (ja) 2010-06-09 2015-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ βセクレターゼ（ＢＡＣＥ）の阻害剤として有用な５，６−ジヒドロ−２Ｈ−［１，４］オキサジン−３−イル−アミン誘導体
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US9840507B2 (en) 2010-12-22 2017-12-12 Janssen Pharmaceutica, Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
BR112013016241A2 (pt) * 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd composto, e, método para fabricar um composto
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US9845326B2 (en) 2011-03-09 2017-12-19 Janssen Pharmaceutica Nv Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8927535B2 (en) * 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
MX2014002113A (es) 2011-08-22 2014-04-25 Merck Sharp & Dohme Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JO3143B1 (ar) 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
CN104245680B (zh) 2012-04-27 2016-11-23 卫材R&D管理有限公司 用于生产5-(二氟甲基)吡嗪-2-甲酸的方法及其生产中间体
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
PT2912041T (pt) 2012-10-26 2017-02-13 Lilly Co Eli Inibidores de bace
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2935256B1 (en) 2012-12-19 2018-01-24 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
US9309263B2 (en) 2013-01-29 2016-04-12 Amgen Inc. Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
KR102220259B1 (ko) 2013-02-12 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 Bace 매개 app 처리과정을 조절하는 히단토인
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
TW201446758A (zh) 2013-03-01 2014-12-16 Amgen Inc 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
KR20150124985A (ko) 2013-03-08 2015-11-06 암젠 인크 베타-세크레타제 억제제로서 퍼플루오르화된 사이클로프로필 융합된 1,3-옥사진-2-아민 화합물 및 그의 사용 방법
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
BR112015030597A2 (pt) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace)
CA2912156C (en) 2013-06-12 2021-07-20 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
JO3318B1 (ar) * 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
US9096615B2 (en) 2013-07-30 2015-08-04 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
CR20160455A (es) 2014-04-10 2016-12-16 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
CA2957544C (en) 2014-08-08 2023-01-24 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
EP3233834B1 (en) 2014-12-18 2019-11-13 Janssen Pharmaceutica NV 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine derivatives useful as inhibitors of beta-secretase
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
EP3271356B1 (en) * 2015-03-19 2019-10-16 Eli Lilly and Company Selective bace1 inhibitors
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
JP2018527338A (ja) * 2015-08-12 2018-09-20 ハー・ルンドベック・アクチエゼルスカベット ＢＡＣＥ１阻害剤としての２−アミノ−７ａ−フェニル−３，４，４ａ，５，７，７ａ−ヘキサヒドロフロ［３，４−ｂ］ピリジン
KR20180033524A (ko) 2015-08-12 2018-04-03 하. 룬드벡 아크티에셀스카브 Bace1 저해제로서의 2-아미노-3-플루오로-3-(플루오로메틸)-6-메틸-6-페닐-3,4,5,6-테트라하이드로피리딘
EP3353183A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
AU2017353510A1 (en) * 2016-11-04 2019-05-02 Janssen Pharmaceutica Nv 4,4a,5,7-tetrahydro-3H-furo[3,4-b]pyridinyl compounds
MA54100A (fr) 2016-12-15 2021-10-20 Amgen Inc Dérivés de thiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
EP3555106B1 (en) 2016-12-15 2022-03-09 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
US10889581B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
US11021493B2 (en) 2016-12-15 2021-06-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
CN110382507A (zh) * 2017-03-07 2019-10-25 詹森药业有限公司 β-分泌酶的抑制剂
KR20190126345A (ko) * 2017-03-07 2019-11-11 얀센 파마슈티카 엔.브이. 베타 세크레타제의 억제제
WO2018162445A1 (en) * 2017-03-07 2018-09-13 Janssen Pharmaceutica Nv Inhibitors of beta secretase
WO2018162443A1 (en) * 2017-03-07 2018-09-13 Janssen Pharmaceutica Nv Inhibitors of beta secretase
US20190389882A1 (en) * 2017-03-07 2019-12-26 Janssen Pharmaceutica Nv Inhibitors of beta secretase
EA201992108A1 (ru) * 2017-09-07 2020-01-27 Янссен Фармацевтика Нв Ингибиторы бета-секретазы
CN110590517A (zh) * 2019-09-24 2019-12-20 武汉嘉诺康医药技术有限公司 一种3，4-二羟基-2′-氯苯乙酮的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101061113A (zh) * 2004-11-23 2007-10-24 默克公司 作为β－内分泌抑制剂用于治疗阿耳茨海默氏病的2,3,4,6－四取代吡啶衍生物
EP2597087B1 (en) 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
CN101360722A (zh) * 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶衍生物及其用途
JP5383483B2 (ja) * 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
ITTO20070665A1 (it) * 2007-09-24 2009-03-25 Rottapharm Spa Derivati amidinici, tioureici e guanidinici di 2-amminobenzotiazoli e amminobenzotiazine, nuovi agenti farmacologici per il trattamento delle patologie neurodegenerative.
HUE026064T2 (en) * 2008-01-18 2016-05-30 Eisai R&D Man Co Ltd Condensed aminodihydrothiazine derivatives
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
ES2539859T3 (es) * 2008-09-30 2015-07-06 Eisai R&D Management Co., Ltd. Nuevo derivado de aminodihidrotiazina condensado

Also Published As

Publication number Publication date
TW201113289A (en) 2011-04-16
DOP2012000004A (es) 2012-01-31
KR20120027482A (ko) 2012-03-21
EA201270149A1 (ru) 2012-06-29
TN2011000673A1 (en) 2013-05-24
WO2011005738A1 (en) 2011-01-13
PE20120632A1 (es) 2012-05-26
BR112012000525A2 (pt) 2015-09-15
CA2764429A1 (en) 2011-01-13
JP2012532874A (ja) 2012-12-20
EP2451793B1 (en) 2016-11-02
EP2451793A1 (en) 2012-05-16
AU2010270691B2 (en) 2013-08-01
ECSP12011581A (es) 2012-02-29
AR077277A1 (es) 2011-08-17
SG177594A1 (en) 2012-02-28
KR101362557B1 (ko) 2014-02-13
HN2012000012A (es) 2014-05-26
ZA201109385B (en) 2013-05-29
US20120323001A1 (en) 2012-12-20
US20110009395A1 (en) 2011-01-13
TWI405765B (zh) 2013-08-21
IL216742A0 (en) 2012-03-01
JP5666578B2 (ja) 2015-02-12
US8278441B2 (en) 2012-10-02
EA019892B1 (ru) 2014-07-30
NZ596579A (en) 2013-12-20
CN102471296A (zh) 2012-05-23
AU2010270691A1 (en) 2011-12-22
MX2012000510A (es) 2012-01-27
MA33492B1 (fr) 2012-08-01
CA2764429C (en) 2014-11-18
CL2012000033A1 (es) 2012-09-14
CN102471296B (zh) 2014-11-12
CO6480979A2 (es) 2012-07-16
AU2010270691B8 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
CR20120011A (es) Inhibidores de bace
DOP2010000328A (es) Inhibidores de bace
GT201300078A (es) Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
HN2012000263A (es) Derivados n1-sulfonil-5-fluoropirimidinona
CR20120121A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
CR20120295A (es) Triazolopiridinas
PT2585437E (pt) Compostos de tioacetato, composições e métodos de uso
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
ECSP10010347A (es) (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
ECSP088740A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
ECSP13012914A (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.
EA201290243A1 (ru) Хиназолиновые соединения
BR112012007577A2 (pt) semigéis de ácido silícico de superfície modificada
DOP2013000284A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
CL2011000932A1 (es) Proceso para la preparacion de 9-diclorometilen-1,2,3,3-tetrahidro-1,4-metano-naftalen-5-ilamina; compuesto intermedio y proceso para preparar 6,6-diclorfulveno.
EA201270397A1 (ru) Тиадиазол, используемый в качестве ускорителя вулканизации, и способ его получения
DOP2006000064A (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidores de la inflamacion